Rabbi Fazle, Banfield Laura, Munir Mehnaz, Chagla Zain, Mayhew Alexandra, de Souza Russell J
Global Health Graduate Programs, McMaster University, Hamilton, Ontario, Canada.
Health Sciences Library, McMaster University, Hamilton, Ontario, Canada.
Heliyon. 2023 Oct 10;9(10):e20563. doi: 10.1016/j.heliyon.2023.e20563. eCollection 2023 Oct.
Empirical use of antibiotics was reported throughout the coronavirus disease of 2019 (COVID-19) pandemic; however, evidence of bacterial coinfection or secondary bacterial infection among COVID-19 patients was sparse. Antibiotic overprescription for COVID-19 patients without confirmed bacterial coinfection can increase antimicrobial resistance (AMR). The objective of this study is to assess the appropriateness of antibiotic use during COVID-19 by summarizing the frequency of antibiotic use among hospitalized COVID-19 and the frequency of antibiotic use in patients with COVID-19.
A systematic search was conducted of the Embase, Medline, Web of Science, and Cochrane Library databases by generating search terms using the concepts of "COVID-19," "Bacterial Coinfection," "Secondary bacterial infection," and "Antimicrobial resistance" to identify studies reporting antibiotic prescription for hospitalized COVID-19 patients with or without bacterial coinfection. We excluded studies on outpatients, studies informed infection due to mechanical ventilation, and randomized controlled trials. The pooled estimate of the percentage of the total and confirmed appropriate antibiotic prescriptions provided to hospitalized COVID-19 patients was generated using a random effect meta-analysis with inverse variance weighting. The study protocol registration DOI is osf.io/d3fpm.
Of 157,623 participants from 29 studies (11 countries, 45 % women) included in our review, antibiotics were prescribed to 67 % of participants (CI 64 %-71 %, P < 0·001), of which 80 % (CI 76 %-83 %, P < 0·001) of prescriptions were for COVID-19 patients without confirmed bacterial coinfections. Antibiotic overprescription varied during different periods of the pandemic and between High-Income and Upper and Lower Middle-Income Countries. We found heterogeneity among the studies ( = 100 %). The risk of bias analysis showed that 100 % of the included studies had the proper sample framing, and we are at low risk of bias due to sampling.
We find greater than expected use of antibiotics to treat hospitalized COVID-19 patients without bacterial coinfections, which may contribute to AMR globally. Concrete guidelines for using antibiotics to treat COVID-19 patients, strict monitoring, and administering Antimicrobial Stewardship are needed to prevent overprescription.
在2019冠状病毒病(COVID-19)大流行期间,有关于经验性使用抗生素的报道;然而,COVID-19患者中细菌合并感染或继发性细菌感染的证据却很少。对未确诊细菌合并感染的COVID-19患者过度开具抗生素会增加抗菌药物耐药性(AMR)。本研究的目的是通过总结住院COVID-19患者中抗生素使用频率以及COVID-19患者中抗生素使用频率,来评估COVID-19期间抗生素使用的合理性。
通过使用“COVID-19”、“细菌合并感染”、“继发性细菌感染”和“抗菌药物耐药性”等概念生成检索词,对Embase、Medline、Web of Science和Cochrane图书馆数据库进行系统检索,以识别报告有或无细菌合并感染的住院COVID-19患者抗生素处方的研究。我们排除了关于门诊患者的研究、因机械通气导致感染的研究以及随机对照试验。使用具有逆方差加权的随机效应荟萃分析得出提供给住院COVID-19患者的总抗生素处方和确诊的适当抗生素处方百分比的合并估计值。该研究方案注册DOI为osf.io/d3fpm。
在我们纳入综述的来自29项研究(11个国家,45%为女性)的157,623名参与者中,67%的参与者(CI 64%-71%,P<0.001)被开具了抗生素,其中80%(CI 76%-83%,P<0.001)的处方是针对未确诊细菌合并感染的COVID-19患者。在大流行的不同时期以及高收入国家与中高收入和中低收入国家之间,抗生素过度处方情况有所不同。我们发现各研究之间存在异质性(I²=100%)。偏倚风险分析表明,纳入的研究中有100%具有适当的样本框架,并且由于抽样我们处于低偏倚风险。
我们发现,在治疗未合并细菌感染的住院COVID-19患者时,抗生素的使用超出预期,这可能在全球范围内导致抗菌药物耐药性。需要制定治疗COVID-19患者的具体抗生素使用指南、进行严格监测并实施抗菌药物管理,以防止过度处方。